Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-11-04 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated November 4, 2022, from Ocumension Therapeutics addressed to non-registered shareholders. It informs recipients about the publication of a circular and notice of an Extraordinary General Meeting (EGM). The letter provides instructions on how shareholders can access the corporate communications online or request printed versions. It explicitly states that the corporate communications include various documents such as directors' reports, annual financial statements, auditors' reports, interim reports, notices of meetings, listing documents, circulars, and proxy forms. The document itself does not contain any financial statements, detailed reports, or substantive financial data but serves as a notification about the availability of these documents and how to obtain them. It is relatively short (7,740 characters) and functions as an announcement of report publication rather than the report itself. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Report Publication Announcement (RPA).
2022-11-04 English
NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated November 4, 2022, from Ocumension Therapeutics to shareholders. It announces the publication of a circular, notice of an extraordinary general meeting (EGM), and a proxy form. The letter informs shareholders that these corporate communications are available on the company's and HKEX's websites and provides instructions on how shareholders can elect to receive future communications in printed or electronic form. The document includes a change request form for shareholders to specify their preferred method of receiving corporate communications. The content is primarily an announcement about the availability and distribution of corporate communications rather than the communications themselves. It does not contain financial statements, management discussion, or detailed report content. The document is relatively short (9101 characters) and serves as a notification of publication rather than the report or circular itself. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Report Publication Announcement (RPA).
2022-11-04 English
Documents on Display
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2022-11-04 English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, NOVEMBER 25, 2022
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for an Extraordinary General Meeting (EGM) of Ocumension Therapeutics. It contains instructions for shareholders to appoint proxies to vote on resolutions at the EGM, including details on voting for or against specific resolutions related to share schemes and mandates. There are no financial statements, management discussion, or detailed financial data present. The document is clearly a meeting-related material intended for shareholder voting purposes, not a report or announcement of financial results or corporate changes. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (9445 characters) supports it being a full proxy form rather than a brief announcement. Hence, the classification is PSI with high confidence.
2022-11-04 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice of an Extraordinary General Meeting (EGM) for Ocumension Therapeutics. It includes details about the meeting date, location, agenda items (such as approval of share scheme mandates and awards), proxy voting instructions, and other procedural information. There is no financial data, audit information, or management discussion present. The document is clearly a meeting notice rather than a report or announcement of voting results. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings, including EGMs.
2022-11-04 English
(1) REFRESHMENT OF THE SCHEME MANDATE LIMIT AND SET OF THE SERVICE PROVIDER SUBLIMIT&#x3b; (2) GRANT TO EMPLOYEE PARTICIPANTS AND CONNECTED TRANSACTION INVOLVING THE PROPOSED CONNECTED GRANT&#x3b; AND
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Ocumension Therapeutics related to the refreshment of the scheme mandate limit, grant to employee participants, connected transactions, and notice of an Extraordinary General Meeting (EGM). It includes detailed definitions, letters from the board, independent board committee, and financial adviser, and a notice of EGM with proxy arrangements. The content is typical of a proxy solicitation and information statement sent to shareholders to inform them about matters to be voted on at a shareholder meeting and to solicit their votes. It is not an annual report, earnings release, or regulatory filing, but rather a detailed circular for shareholder voting purposes. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2022-11-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.